Mycobacterial Lung Diseases in Virginia: Sequencing and Clinical Determinants of Relapse and Outcome

Inclusion Criteria: * All subjects: * Race/ethnicity: any * Subject has no history of active Tuberculosis in the last 2 years. * NTM culture positive from respiratory specimen (sputum or bronchial lavage fluid) * Subject must have an available sputum sample that was taken in the last 2 years. If a sample is not available, the subject must be willing and able to provide a sputum sample. * Meets the following Infectious Diseases Society of America (IDSA) criteria for NTM lung disease: * 2 or more sputum (or 1 bronchoscopy/biopsy) cultures positive for "Mycobacterium Avium Complex" or "Mycobacterium abscessus) within the last 2 years. * Nodules, cavities, and/or bronchiectasis on CT scan within the past 2 years * If if the above data are not available, but a patient's Infectious Disease or Pulmonary physician has documented the diagnosis of NTM lung disease in their notes, this will suffice PK subjects: * Newly diagnosed with NTM lung disease and beginning antibiotics for NTM within the last 3 months from enrollment. * Prior diagnosis of NTM lung disease, and starting initial therapy within the last 3 months prior to enrollment. * Consent to pharmacokinetic testing within one month of enrollment and at six months of therapy Exclusion Criteria: * List the criteria for exclusion All subjects: * Age \< 18 years * Subject has cystic fibrosis or other inherited disorders of airway ciliary dysfunction (eg, primary ciliary dyskinesia) * Unable to participate in follow-up requirements by phone or clinic visit PK subjects: • Unable to have blood drawn for pharmacokinetic testing